Heart Failure
Conditions
Brief summary
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body. Renal impairment which co-occurs in patients with heart failure is a common condition in which the kidneys are not filtering the blood as well as they should. The goal of the study was to learn more about the safety of vericiguat (BAY1021189), how it was tolerated and the way the body absorbed, distributed and excreted the study dug given as a single oral dose of 2.5 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight. The participants stayed at the trial site for about 6 days. During this time, the doctors took blood and urine samples and checked the participants' health. About 7-14 days after the participants took vericiguat (BAY1021189), the researchers checked the participants' health again and asked about any medical problems they had.
Interventions
Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Sponsors
Merck Sharp & Dohme LLC
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
Yes
Inclusion criteria
For all subjects: * Aged between 18 and 79 years (inclusive) with body mass index 18 to 34 kg/m\^2 (both inclusive) * Women without childbearing potential; women of childbearing potential only if the pregnancy test was negative and a combination of condoms with a safe and highly effective contraception method was granted For subjects with renal impairment: * With an estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73m\^2 determined from a serum creatinine control 2-14 days prior to dosing * Stable renal disease, i.e. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit For healthy subjects: * eGFR ≥ 90 mL/min/1.73m\^2 determined from serum creatinine 2-14 days prior to dosing * Healthy subjects with age-, weight- and gender- matched to renal impaired subjects
Exclusion criteria
For all subjects: * Febrile illness within 1 week before the start of the study * History of severe allergies, non-allergic drug reactions, or multiple drug allergies * Hypersensitivity to the investigational drug, the control agent and/ or to inactive constituents * Regular daily consumption of more than 1/2 liter of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form or more than 1 liter of xanthine-containing beverages or more than 10 cigarettes * Positive testing in the drug screening * Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2) * Donation of more than 100 mL of blood in the preceding 4 weeks or 500 mL in the preceding 3 months * Relevant deviation from the normal range in clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator For subjects with renal impairment * Acute renal failure * Acute nephritis * Any organ transplant in the past 5 years * Severe cerebrovascular or cardiac disorders, e.g. myocardial infarction less than 6 months prior to dosing, congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring anti-arrhythmic treatment * Percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to dosing * Diagnosed malignancy within the past 5 years * Failure of any other major organ system other than the kidney * Concomitant use of any medication except medications necessary for the treatment of diseases * Diastolic BP \>100 mmHg and/or systolic BP \>180 mmHg * Heart rate below 50 beats/min or above 100 beats/min at screening visit * Significant uncorrected rhythm or conduction disturbances For healthy subjects * Subjects with conspicuous findings in medical history or pre-study examination * A history of relevant diseases of vital organs, of the central nervous system or other organs * Excluded therapies (e.g. physiotherapy, acupuncture, etc.) from 1 week before admission to the ward (-01d) * Use of medication within the 2 weeks preceding the study which could interfere with the investigational product * Systolic BP below 100 mmHg or above 145 mmHg and Diastolic BP below 55 mmHg or above 95 mmHg * Heart rate below 50 beats/min or above 100 beats/min * Clinically relevant findings in the electrocardiogram (ECG)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC of vericiguat | Up to 96 hours | Area under the concentration vs. time curve from zero to infinity after single dose administration |
| Cmax of vericiguat | Up to 96 hours | Maximum observed drug concentration in measured matrix after single dose administration |
| AUC of vericiguat's metabolite M-1 | Up to 96 hours | Area under the concentration vs. time curve from zero to infinity after single dose administration |
| Cmax of vericiguat's metabolite M-1 | Up to 96 hours | Maximum observed drug concentration in measured matrix after single dose administration |
Countries
Germany
Outcome results
None listed